Jump to ContentJump to Main Navigation
Economic Dimensions of Personalized and Precision Medicine$
Users without a subscription are not able to see the full content.

Ernst R. Berndt, Dana P. Goldman, and John Rowe

Print publication date: 2019

Print ISBN-13: 9780226611068

Published to Chicago Scholarship Online: September 2019

DOI: 10.7208/chicago/9780226611235.001.0001

Show Summary Details
Page of

PRINTED FROM CHICAGO SCHOLARSHIP ONLINE (www.chicago.universitypressscholarship.com). (c) Copyright University of Chicago Press, 2022. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in CHSO for personal use.date: 26 May 2022

Therapeutic Translation of Genomic Science

Therapeutic Translation of Genomic Science

Opportunities and Limitations of GWAS

Chapter:
(p.21) 2 Therapeutic Translation of Genomic Science
Source:
Economic Dimensions of Personalized and Precision Medicine
Author(s):

Manuel Hermosilla

Jorge Lemus

Publisher:
University of Chicago Press
DOI:10.7208/chicago/9780226611235.003.0003

Many scientists predicted a swift revolution in human therapeutics after the completion of the Human Genome Project (“HGP”). This revolution, however, has been slow to materialize in spite of the scientific advances. We investigate the role of biological complexity in slowing down this revolution. Our test relies on a disease-specific measure of biological complexity, constructed by drawing on insights from Network Medicine (Barabási et al. 2011). According to our measure, more complex diseases are associated with a larger number of genetic mutations—higher centrality in the Human Disease Network (Goh et al. 2007). With this measure in hand, we estimate the rate of translation of new science into early-stage drug innovation by focusing on a leading type of genetic epidemiological knowledge (Genome-Wide Association Studies) and employing standard methods for the measurement of R&D productivity. For less complex diseases, we find a strong and positive association between cumulative knowledge and the amount of innovation. This association weakens as complexity increases, becoming statistically insignificant at the extreme. Our results suggest that biological complexity is, in part, responsible for the slower-than-expected unfolding of the therapeutical revolution set in motion by the HGP.

Keywords:   Pharmaceuticals, Genetics, Genome, Innovation, Therapeutical Translation, Network Medicine, GWAS

Chicago Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.